REDWOOD CITY, Calif. , Feb. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares